TP53 and neoplasm: In metastatic gallbladder cancer, Soni et al. reported a case with both EGFR T790M and TP53 mutations that responded dramatically to erlotinib combined with chemotherapy, achieving a 90% reduction in tumor size and a median PFS of 11 months [54].